BCG vaccine

End Drug Shortages Alliance Announces New Chair and Board Members for 2024

Retrieved on: 
Tuesday, January 23, 2024
Thought Leadership, Pharmaceutical, General Health, Health, Mental Health, Hospitals, Professional Services, Other Health, BCG vaccine, FCCP, Bladder cancer, Knowledge, Doctor of Pharmacy, Policy, Communication, Mayo Clinic, Risk, Pharmacy, Ochsner Health System, MBA, Technology policy, Tichy, White, Organization, Bacillus, EDSA, Risk management

The End Drug Shortages Alliance (EDSA) announces the appointment of Terri Lyle Wilson, vice president of pharmacy for The Children’s Hospital Association, as its new chair.

Key Points: 
  • The End Drug Shortages Alliance (EDSA) announces the appointment of Terri Lyle Wilson, vice president of pharmacy for The Children’s Hospital Association, as its new chair.
  • Wilson succeeds past-board chair Eric Tichy, PharmD, MBA, FCCP, division chair, pharmacy supply solutions, Mayo Clinic.
  • Tichy helped launch the End Drug Shortages Alliance in 2021 and was appointed chair in December 2021.
  • "I am very grateful to Eric for his leadership and am honored to step into the role of board chair for the End Drug Shortages Alliance," said Wilson.

Verana Health Announces Release of Qdata Module for Non-Muscle Invasive Bladder Cancer RWE Analysis

Retrieved on: 
Monday, February 13, 2023
American Urological Association, Bladder cancer, Cancer, Woman, Health, Millennium, RWD, Diagnosis, Oncology, Natural language processing, BPH, Patient, HIV disease progression rates, Artificial intelligence, Research, Neoplasm, Urology, Risk, NMIBC, NLP, BCG vaccine, AUA, Disease, EHR, FDA, SAN, AQUA, Partnership, Health information management, Machine learning, BCG, AI, MD, Pharmaceutical industry, Medical imaging, Nursing

SAN FRANCISCO, Feb. 13, 2023 /PRNewswire/ -- Verana Health®—a digital health company elevating quality in real-world data (RWD)—today announced that a Urology Qdata®module is available to help support clinical research surrounding non-muscle invasive bladder cancer (NMIBC). This highly curated module will help facilitate a more comprehensive view of the NMIBC patient journey including disease progression over time. Exclusive insights into more than 50,000 de-identified patients with NMIBC are derived from key variables extracted from unstructured clinician notes including diagnosis date, treatments, recurrences, documented T stage, and tumor grade for risk determination. These exclusive therapeutic insights can be used to help better understand treatment patterns and outcomes to inform therapeutic strategies for patients with this disease.

Key Points: 
  • SAN FRANCISCO, Feb. 13, 2023 /PRNewswire/ -- Verana Health ®—a digital health company elevating quality in real-world data (RWD)—today announced that a Urology Qdata ® module is available to help support clinical research surrounding non-muscle invasive bladder cancer (NMIBC).
  • Verana Health has an exclusive partnership with the AUA to de-identify, curate, and analyze electronic health record (EHR) data from the AQUA Registry.
  • Bladder cancer is the sixth-most common cancer in the U.S. and ninth-most common cancer in the world.
  • Verana Health announced the launch of Urology Qdata and the release of the first urology module (Qdata Prostate Cancer) in May 2022.

2022 Bladder Cancer Update Bulletin: Key Opinion Leader (KOL) Views on Recent Developments - ResearchAndMarkets.com

Retrieved on: 
Monday, November 28, 2022
Pharmaceutical, Health, Oncology, IDO, Bladder cancer, BCG vaccine, PD-1, Risk, NMIBC, Patient, BMS, Phase, Toxicity, IDO1, BCG, Bristol Myers Squibb, PD-L1, Immunotherapy, KOL, Pharmaceutical industry, Medical device, Nivolumab

The "Bladder Cancer: Update Bulletin #2" newsletter has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bladder Cancer: Update Bulletin #2" newsletter has been added to ResearchAndMarkets.com's offering.
  • This edition presents leading key opinion leader (KOL) views on recent developments in the Bladder Cancer market.
  • How do the KOLs perceive the Phase II combination results for BMS' Opdivo with the IDO inhibitor BMS-986205 in patients with advanced bladder cancer?
  • What are experts' thoughts on PD-L1 expression and its future use as a biomarker in patients with bladder cancer?

Modified bladder cancer treatment shows promise in animal studies

Retrieved on: 
Tuesday, August 23, 2022
Inflammation, Patient, Cancer, Lipid, Research, Bladder cancer, SAN, Death, Doctor of Philosophy, Disease, Man, BCG, Texas Biomedical Research Institute, Southwest Research Institute, University of Texas Health Science Center at San Antonio, Quality of life, American Cancer Society, Cell, Cancer immunology, BCG vaccine, MD, FDA, Tuberculosis, Clinical trial, Woman, Industry, Drug development, UT Health San Antonio Cancer Center, Bacteria, Dietary supplement, Pharmaceutical industry, Vaccine, Medical device, Immunotherapy, TB, Mycobacterium

SAN ANTONIO, Aug. 23, 2022 /PRNewswire/ -- A modified tuberculosis vaccine developed at Texas Biomedical Research Institute could help treat a form of bladder cancer, called non-muscle invasive bladder cancer, without strong side effects.

Key Points: 
  • SAN ANTONIO, Aug. 23, 2022 /PRNewswire/ -- A modified tuberculosis vaccine developed at Texas Biomedical Research Institute could help treat a form of bladder cancer, called non-muscle invasive bladder cancer, without strong side effects.
  • A modified TB vaccine developed at Texas Biomed could help treat a type of bladder cancer without strong side effects.
  • About 75% of bladder cancer cases are classified as non-muscle invasive, which means the cancer affects the tissue lining the inner surface of the bladder, but not the bladder muscle.
  • Dr. Svatek's lab conducted the tests in a mouse model of bladder cancer and in cells collected from human cancer patients.

Global BCG Vaccine Market to 2030 - Opportunity Analysis and Industry Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 15, 2022
Health, Pharmaceutical, Growth, Incidence, CAGR, BCG, Pediatrics, Anthrax Vaccine Immunization Program, BCG vaccine, TB, Research, Prevalence, Tuberculosis, Vaccine

The "BCG Vaccine Market by Demographics (Pediatric and Adults: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "BCG Vaccine Market by Demographics (Pediatric and Adults: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global BCG vaccine market was valued at $46,637.5 thousands in 2020, and is projected to reach $74,269.55 thousands by 2030, registering a CAGR of 4.8% from 2021 to 2030.
  • The global BCG vaccine market is driven by increase in prevalence of tuberculosis and rise in technological advancements in vaccine research.
  • However, side effects of BCG vaccine and the global shortage of BCG vaccine restrain this growth.

COVID-19: Does having received the BCG vaccine as a child provide a protective effect?

Retrieved on: 
Monday, October 25, 2021
Research, Interdisciplinarity, Technology, PCR, Vaccine, Industry, INRS, Survival, Vaccination, Child, Society, Newsroom, BCG, Infection, Varennes-en-Argonne, HMR, Epidemiology, Elsevier, Giovanni Bacile, COVID-19, DOI, Growth, BCG vaccine, Microbiology, Laboratory, Mortality, Population, Universitate metro station, Entrepreneurship, Heart, Tuberculosis, Institute, Center, Student, Management, Animal, Pharmaceutical industry

The research , published in the Vaccine journal, brings new light on the possible link between the BCG vaccine and COVID-19.

Key Points: 
  • The research , published in the Vaccine journal, brings new light on the possible link between the BCG vaccine and COVID-19.
  • "Our study has shownconvincingly that BCG, a strong stimulator of innate immunity, does not confer very long-term protection against COVID-19.
  • Among those who tested positive for COVID-19, 54% had received the BCG vaccine during childhood.
  • Among those who had received the vaccine more recently, in the early 1970s, no protective effect was also observed.

LintonPharm Announces Authorization from China Health Authority (NMPA) to Proceed with a Phase 1/2 Trial Evaluating Catumaxomab for the treatment of Non-Muscle Invasive Bladder Cancer

Retrieved on: 
Tuesday, April 13, 2021
Research, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Infectious causes of cancer, Bladder cancer, Aging-associated diseases, Cancer, Urinary bladder, Clinical medicine, Health, BCG vaccine, Catumaxomab, LintonPharm

\xe2\x80\x9cPatients with NMIBC BCG failure have high rates of tumor recurrence and often face a lifetime of surgical intervention which may impact bladder function.

Key Points: 
  • \xe2\x80\x9cPatients with NMIBC BCG failure have high rates of tumor recurrence and often face a lifetime of surgical intervention which may impact bladder function.
  • New treatment options are needed and we are hopeful that this study puts us one step closer toward helping these patients.\xe2\x80\x9d\nBladder cancer is the 10th most common cancer worldwide.
  • In 2020, bladder cancer was diagnosed in approximately 573,278 patients globally and approximately 1.8 million people were living with this form of cancer over a five-year period [1].
  • NMIBC is a cancer found in the tissue that lines the inner surface of the bladder and accounts for approximately 75 percent of all bladder cancer [2].

ImmunityBio Announces ASCO Genitourinary Cancer Symposium Presentation of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 71% Complete Response Rate

Retrieved on: 
Tuesday, February 16, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Infectious causes of cancer, Bladder cancer, Aging-associated diseases, Clinical medicine, Cancer, Medical specialties, Urinary bladder disorders, Histopathology, Carcinoma, BCG vaccine, Hexyl aminolevulinate hydrochloride

Patients with BCG unresponsive CIS disease face surgical removal of the bladder, a procedure fraught with high morbidity and mortality.

Key Points: 
  • Patients with BCG unresponsive CIS disease face surgical removal of the bladder, a procedure fraught with high morbidity and mortality.
  • Bladder cancer has a high incidence worldwide; it caused 212,536 deaths and an estimated 573,278 new cases were diagnosed in 20201.
  • Approximately 75-85% of all newly diagnosed cases of bladder cancer are non-muscle invasive bladder cancer (NMIBC)3.
  • The primary endpoint for Cohort A of this Phase 2/3 study is incidence of complete response (CR) of CIS at any time.

 ImmunityBio Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate

Retrieved on: 
Monday, December 21, 2020
Research, FDA, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Infectious causes of cancer, Bladder cancer, Medicine, Clinical medicine, Aging-associated diseases, Clinical endpoint, Health, Cancer, Surgery, BCG vaccine

Patients with BCG unresponsive CIS disease face surgical removal of the bladder, a procedure fraught with high morbidity and mortality.

Key Points: 
  • Patients with BCG unresponsive CIS disease face surgical removal of the bladder, a procedure fraught with high morbidity and mortality.
  • Approximately 75-85% of all newly diagnosed cases of bladder cancer are non-muscle invasive bladder cancer (NMIBC)3.
  • The primary endpoint for Cohort A of this Phase 2/3 study is incidence of complete response (CR) of CIS at any time.
  • In December 2019, the FDA granted ImmunityBio Breakthrough Therapy Designation based on interim Phase 2 data indicating the primary endpoint of the trial was already met.

New Data Analyses from Phase 3 Study of Investigational Gene Therapy Nadofaragene Firadenovec Presented at Society of Urologic Oncology Annual Meeting

Retrieved on: 
Wednesday, December 2, 2020
Branches of biology, Biology, Life sciences, Biotechnology, Antivirals, Cytokines, Bladder cancer, Interferon, Adenoviridae, Gene therapy, BCG vaccine

In the study, nadofaragene firadenovec was administered directly into the patients bladder once every three months by a healthcare professional.

Key Points: 
  • In the study, nadofaragene firadenovec was administered directly into the patients bladder once every three months by a healthcare professional.
  • Nadofaragene firadenovec (rAd-IFN/Syn3) is an investigational gene therapy being developed as a treatment for patients with high-grade, BCG-unresponsive NMIBC.
  • It is a non-replicating adenovirus vector-based gene therapy containing the gene interferon alfa-2b, administered by catheter into the bladder once every three months.
  • 3 Narayan, V. Subgroup Analyses of the Phase 3 Study of Intravesical Nadofaragene Firadenovec in Patients with High-Grade, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC).